Rosetta to Debut Array-Based Cancer-of-Unknown-Primary Test in H2
March 23, 2010
Rosetta to Debut Array-Based Cancer-of-Unknown-Primary Test in H2
CEO Kenneth Berlin said that the next-generation version of Rosetta's miRview Mets test will run on an array platform, and that the firm's CLIA lab was recently upgraded to include a microarray room to process the test.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.